Low‐molecular‐weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study

Zezos, Petros; Papaioannou, Georgia; Nikolaidis, Nikolas; Patsiaoura, Kalliopi; Papageorgiou, Athanasios A.; Vassiliadis, Themistoklis; Γιουλεμέ, Όλγα; Evgenidis, Nikolaos

doi:10.1111/j.1365-2036.2006.02870.x

Cited by 41 publications

(35 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other trials have examined treatment with low molecular weight heparin. In one randomized trial including only patients with UC, the 16 patients who received full anticoagulant doses of low molecular weight heparin had no episodes of rectal bleeding and only small hematomas at the injection site [22] . In a larger, randomized, controlled trial of 48 patients with UC who received low molecular weight heparin, first at full anticoagulation doses, and later at a dose equivalent to that used for prevention of deep venous thrombosis, there were no complications in the treatment group and one episode of rectal bleeding in the placebo group [23] .…”

Section: Discussionmentioning

confidence: 99%

Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events

Wang¹,

Terdiman²,

Vittinghoff³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To compare thromboembolism rates between hospitalized patients with a diagnosis of ulcerative colitis and other hospitalized patients at high risk for thromboembolism. To compare thromboembolism rates between patients with ulcerative colitis undergoing a colorectal operation and other patients undergoing colorectal operations. METHODS:Data from the National Hospital Discharge Survey was used to compare thromboembolism rates between (1) hospitalized patients with a discharge diagnosis of ulcerative colitis and those with diverticulitis or acute respiratory failure, and (2) hospitalized patients with a discharge diagnosis of ulcerative colitis who underwent colectomy and those with diverticulitis or colorectal cancer who underwent colorectal operations. RESULTS:Patients diagnosed with ulcerative colitis had similar or higher rates of combined venous thromboembolism (2.03%) than their counterparts with diverticulitis (0.76%) or respiratory failure (1.99%), despite the overall greater prevalence of thromboembolic risk factors in the latter groups. Discharged patients with colitis that were treated surgically did not have significantly different rates of venous or arterial thromboembolism than those with surgery for diverticulitis or colorectal cancer. CONCLUSION:Patients with ulcerative colitis who do not undergo an operation during their hospitalization have similar or higher rates of thromboembolism than other medical patients who are considered to be high risk for thromboembolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events

Wang¹,

Terdiman²,

Vittinghoff³

et al. 2009

WJG

View full text Add to dashboard Cite

show abstract

“…Based on these observations, heparin was used to treat or prevent thromboembolic events in UC patients (7)(8)(9)(10)(11). However, the efficacy of anticoagulant therapy, such as heparin, in UC patients remains controversial (7)(8)(9)(10)(11)(12).…”

Section: In Patients With Inflammatory Bowel Disease (Ibd) Mucosal Amentioning

confidence: 99%

Activations of Coagulation and Fibrinolysis Secondary to Bowel Inflammation in Patients with Ulcerative Colitis

et al. 2007

View full text Add to dashboard Cite

Background Recent investigations suggest that activation of coagulation and fibrinolysis occurs in patients with ulcerative colitis (UC). activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT), serum concentrations of von Willebrand factor (vWF), activated factors XII, XI, X, IX, VIII, VII, V, II, fibrinogen, prothrombin fragments 1+2 (F1+2), thrombin-antithrombin complexes (TAT), protein S, protein C, plasminogen, α-2 plasminogen inhibitor (α-2PI) and D-dimer (D-D). Results Median serum vWF concentrations, F1+2, TAT, fibrinogen, activated factor XI, IX, VIII and V were significantly elevated in patients with active UC and IC compared to those in patients with

show abstract

“…Current medical treatment of IBD, titrated according to the severity of the disease and to the individual response, includes 5-aminosalicylic acid (ASA) derivatives, corticosteroids, immunosuppressants, and most recently biologic agents mainly targeted against tumor necrosis factor (TNF)-a. Among the emerging treatments for ulcerative colitis, the parenteral administration of low-molecular-weight heparins (LMWHs), i.e., dalteparin, enoxaparin, nadroparine, reviparin, deligoparin, and tinzaparin, was judged clinically useful by some authors [1][2][3], but questioned by others [4][5][6][7][8]. The administration of LMWHs by oral route has recently been attempted, resulting safe and effective in corticosteroid-resistant UC patients [9].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Intracolonic Administration of Low-Molecular-Weight Heparin CB-01-05, Compared to Other Low-Molecular-Weight Heparins and Unfractionated Heparin, in Experimentally Induced Colitis in Rat

et al. 2008

View full text Add to dashboard Cite

Purpose Parenteral administration of lowmolecular-weight heparins (LMWHs) and unfractionated heparin (UFH) resulted effective in improving the symptoms of experimental colitis in rat. Today, there is little information about their activity by intracolonic instillation. The scope of this study was to evaluate the ability of CB-01-05 (a LMWH with a mean molecular weight of about 5,700), compared to a series of other LMWHs and to UFH, directly instilled into the distal colon of the rat, to ameliorate dinitrobenzene (DNB)-induced experimental colitis. Method Adult male Wistar rats underwent colitis induction by intracolonic instillation of DNB. Starting 24 h after colitis induction, CB-01-05 (0.005-0.9 mg), other LMWHs (0.3-0.6 mg), and UFH (0.6 mg) were instilled, by rectal route, into the distal colon once a day for three consecutive days. On the day following the last administration, the animals were sacrificed and the distal colon was isolated, weighed, macroscopically examined, and processed for histology. Additional experiments in rat splenocytes, performed in order to elucidate the anti-inflammatory mechanisms of CB-01-05, were performed. Results Among the tested items, only CB-01-05 at doses ranging from 0.2 to 0.9 mg was significantly effective in reducing colon weight increase and in improving both the mucosal damaged area and the histological score. The other LMWHs resulted far less effective, showing decreasing activity closely related with the decrease of their molecular weight, thus demonstrating their biological nonequivalence. CB-01-05 resulted also more active than UFH. CB-01-05 was shown to interfere with cytokines production by rat splenocytes, mainly inhibiting interferon (IFN)-c expression. Conclusions CB-01-05 instilled into the colon is well tolerated, has strong anti-inflammatory effect on DNBinduced colitis in rat, and is the most effective agent among other LMWHs and UFH. These results suggest that the anti-inflammatory activity of CB-01-05, together with its topical administration, could represent a new approach in the management of ulcerative colitis.

show abstract

Low‐molecular‐weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study

Abstract: SUMMARY BackgroundHeparin could be beneficial to the treatment of active ulcerative colitis because of its anticoagulant, anti-inflammatory and immunomodulatory properties.

Cited by 41 publications

References 37 publications

Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events

Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events

Activations of Coagulation and Fibrinolysis Secondary to Bowel Inflammation in Patients with Ulcerative Colitis

Efficacy of Intracolonic Administration of Low-Molecular-Weight Heparin CB-01-05, Compared to Other Low-Molecular-Weight Heparins and Unfractionated Heparin, in Experimentally Induced Colitis in Rat

Contact Info

Product

Resources

About